Long-term efficacy of low activity meta-[i]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response

Nuclear Medicine Communications

Volumn 26, Issue 11, 2005, Pages 969-976

  Buscombe, John R ^a   Cwikla, Jaroslaw B ^a   Caplin, Martyn E ^a   Hilson, Andrew J W ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Neuroendocrine tumours; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ADULT; AGED; BLOOD ANALYSIS; BONE MARROW; CALCULATION; CANCER SURVIVAL; CARCINOID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; GASTRINOMA; HUMAN; KIDNEY; LIVER; MALE; MEDICAL ASSESSMENT; NAUSEA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REVIEW; SOLID TUMOR; SURVIVAL TIME; THYROID CARCINOMA; THYROID GLAND; TIME SERIES ANALYSIS; TOXICITY; TREATMENT OUTCOME; TUMOR VOLUME; URINALYSIS;

3-IODOBENZYLGUANIDINE; ADULT; AGED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 27344451255     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000184941.06123.b9     Document Type: Article

References (23)

1. Ramage JK, Williams R, Buxton-Thomas M. Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). Q J Nucl Med 1996; 89:539-542.
2. Wafelman AR, Hoefnagel CA, Maes RAA, Beijnen JH. Radio-iodinated meta-iodobenzylguanidine: a review of pharmacokinetics, drug interaction, cytotoxicity and dosimetry. Eur J Nucl Med 1994; 21:545-559.
3. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996; 14:1829-1838.
4. Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 2003; 89:1383-1388.
5. Sission JC, Frager MS, Valek TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981; 305:12-17.
6. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin N Am 1993; 22:941-952.
7. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352:799-805.
8. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94:1381-1387.
9. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999; 17:474-478.
10. Shapiro B. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks. Q J Nucl Med 1995; 39(suppl 1-4):150-155.
11. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994; 21:561-581.
12. 131I-mIBG). Clin Endocrinol 2001; 55:47-60.
13. 131I-mIBG): a comprehensive review of 116 reported patients. J Endocrinol Ivest 1997; 20:648-658.
14. 131I-metaiodobenzylguanidine. Nucl Med Commun 1993; 14:856-861.
15. Bongers V, de Klerk JM, Zonnenberg BA, de Kort G, Lips CJ, van Rijk PP. Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors. J Nucl Med 1997; 38:1024-1026.
16. 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol 2001; 27:404-408.
17. 131I-MIBG therapy. Clin Oncol 2003; 15:193-198.
18. 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002; 29:1581-1587.
19. Caplin ME, Mielcarek W, Buscombe JR, Jones AL, Croasdale PL, Cooper MS, et al. Toxicity of high activity In-111-octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000; 21:97-102.
20. 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumours. J Nucl Med 2003; 44:1-6.
21. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432-445.
22. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004; 101:1987-1993.
23. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 2004; 28:1157-1162.